Phase II proof of concept clinical study pipeline

The development of an effective treatment for HBV and HBV / HDV infection will require a combination treatment. Small scale adaptive proof of concept clinical trials have allowed Replicor to rapidly assess the following:

  1. NAP dosing regimens which are well tolerated and effective in removing serum HBsAg.
  2. Efficacy of NAP regimens in different ethnic patient populations.
  3. Tolerability of immunotherapy and NUC therapy in the presence of NAP backbone therapy.
  4. Optimization of NAP-based combination therapy to achieve the highest SVR rates possible (functional cure).
  5. Selection of first NAP candidate for continued development to NDA (REP 2139).

Replicor’s current clinical pipeline: